Your session is about to expire
← Back to Search
NBTXR3 + Radiation Therapy for Pancreatic Cancer
Study Summary
This trial is testing a new drug, NBTXR3, to see if it can help treat pancreatic cancer when used with radiation therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or can carry out light work.I have had surgery to remove a pancreatic tumor.I have pancreatic cancer and no other active cancers, except for treated and cured skin cancer.I do not have serious heart rhythm problems.I have had radiation therapy to my upper abdomen.You cannot have a medical procedure that involves contrast dye containing iodine or gadolinium.I am willing to undergo a special ultrasound-guided injection as my doctor advises.I am not pregnant or breastfeeding.Criterion Summary: Your blood tests must show certain levels within a normal range, and females must have a negative pregnancy test. If you have a specific type of stent in your body, it may need to be replaced before the study starts.I haven't had severe stomach or duodenal ulcers in the last month.I have not taken any cancer treatment drugs other than those listed in this study.I do not have an active, uncontrolled HIV or hepatitis B/C infection.I have severe heart failure diagnosed within the last 6 months.I've completed a 4-month chemotherapy for pancreatic cancer without signs of it spreading.I am using a highly effective birth control method during the study.I am 18 years old or older.My cancer has spread to distant parts of my body, as shown by scans.My cancer is not pancreatic ductal adenocarcinoma.My diagnosis is biopsy-proven pancreatic cancer.My pancreatic cancer can be measured and tracked using scans.
- Group 1: Treatment (NBTXR3, radiation therapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA granted its stamp of approval to using Hafnium Oxide-containing Nanoparticles NBTXR3?
"Due to limited clinical data on the efficacy and safety of Hafnium Oxide-containing Nanoparticles NBTXR3, our team at Power rated it as a 1."
How many test subjects are engaged in this research endeavor?
"Affirmative. According to clinicaltrials.gov, this research endeavour commenced on July 1st 2020 and was recently updated on September 28th 2022. It is hoped that 24 participants can be enrolled from a single site of invitation."
Are there vacancies available for participants in this research program?
"Affirmative. According to information published on clinicaltrials.gov, the study is currently seeking participants and was initially posted on July 1st 2020 with an update made in September 28th 2022. The trial requires 24 patients from a single site."
Share this study with friends
Copy Link
Messenger